Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2/PHASE3
INTERVENTIONAL
2005-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Research Study to Test Safety and Effectiveness of Investigational Drug in Patients With Trigeminal Neuralgia
NCT00203229
Drug Use Investigation for LAMICTAL
NCT01376180
Observational Study of Lamotrigine
NCT00299793
Study Of The Safety And Efficacy Of Lyrica In The Treatment Of Newly Diagnosed Partial Epilepsy
NCT00280059
Conversion To Monotherapy With Lamictal Extended Release Tablets For Treatment Of Partial Epilepsy
NCT00355082
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Lamictal in the treatment of Post-Herpetic Neuralgia
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Need to have a diagnosis of Post-Herpetic Neuralgia,
* Minimum of 4 on the Likert Pain Scale,
* If currently taking TCA and/or Gabapentin, need to have been on stable dose for minimum of 4 weeks
Exclusion Criteria
* Currently taking opioid or unwilling to washout prior to the study,
* Pregnant and lactating,
* Have active severe systemic disease,
* History of Stevens-Johnson syndrome or TEN,
* Clinically significant abnormal lab values,
* Known drug allergy to Lamictal,
* Patients on Fibrates (Tricor and Lopid),
* History of major psychiatric disturbance and substance abuse.
* Valproate due to increase chances of severe rash,
* Lidocaine Patch,
* Use of hormonal contraceptives (birth control pills, patch, ring, injection)
18 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
George Washington University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Perry K. Richardson, M.D.
Role: PRINCIPAL_INVESTIGATOR
The George Washington University Medical Faculty Associates
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Medical Faculty Associates
Washington D.C., District of Columbia, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Lamictal PHN
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.